Valuation: Becton, Dickinson and Company

Market Cap 42.39B 37.15B 34.43B 31.69B 59.75B 4,082B 60.47B 411B 161B 2,001B 159B 156B 6,908B P/E 2026 *
38.3x
P/E 2027 * 29.6x
Enterprise Value 58.9B 51.63B 47.84B 44.03B 83.03B 5,673B 84.03B 571B 223B 2,780B 221B 216B 9,599B EV / Sales 2026 *
3.07x
EV / Sales 2027 * 2.86x
Free-Float
74.04%
Yield 2026 *
2.5%
Yield 2027 * 2.54%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-2.23% - - 42.39B
-1.96%+12.04%-19.89%-12.79% 174B
-1.13%+3.85%-8.19%-7.43% 105B
-0.30%+0.26%+3.55%+57.37% 58.97B
-1.59%-1.13%+39.37%+57.81% 52.24B
+0.54%+1.11% - - 33.05B
-1.24%+0.85%-11.04%-42.76% 28.84B
+1.96%+0.44%+71.00%-4.79% 25.38B
-1.27%+1.45%-4.90%-8.76% 20.64B
-1.85%+0.89%-6.76%-1.26% 20.28B
Average -0.54%+2.21%+7.89%+4.67% 57.6B
Weighted average by Cap. -0.95%+5.01%-1.66%+3.79%

Financials

2026 *2027 *
Net sales 19.21B 16.84B 15.6B 14.36B 27.08B 1,850B 27.41B 186B 72.88B 907B 72.12B 70.57B 3,131B 19.73B 17.29B 16.02B 14.74B 27.8B 1,900B 28.14B 191B 74.82B 931B 74.04B 72.45B 3,215B
Net income 1.12B 986M 913M 841M 1.59B 108B 1.6B 10.9B 4.27B 53.08B 4.22B 4.13B 183B 1.45B 1.27B 1.18B 1.08B 2.04B 140B 2.07B 14.05B 5.5B 68.4B 5.44B 5.32B 236B
Net Debt 16.51B 14.47B 13.41B 12.34B 23.28B 1,590B 23.56B 160B 62.64B 779B 61.99B 60.66B 2,691B 13.96B 12.23B 11.34B 10.43B 19.67B 1,344B 19.91B 135B 52.94B 659B 52.39B 51.27B 2,275B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Trader
Investor
Global
Quality
ESG MSCI
-